

L'ORÉAL

L'Oréal signs license agreement with Dutch biotech Microeos, world leader in targeted bacterial biotechnology

Clichy / The Hague, 29 October 2020 – L'Oréal and Microeos announced today the signature of a license agreement to join their expertise in biotechnology and the skin microbiome, the community of bacteria and microorganisms that live on the skin. Under the terms of the agreement, Microeos will give L'Oréal access to its endolysin, a type of active protein in the cosmetic field. With this technology, it is possible for the first time to target only unwanted bacteria in the skin flora - responsible for many skin problems - while sparing the good ones.

For 15 years, L'Oréal's Research & Innovation has been cooperating with scientific institutions and conducting clinical studies to better understand the role of the skin microbiome. *"The agreement with Microeos opens up a very promising field in high-tech cosmetics"*, says **Laurent Attal, Executive Vice-President Research & Innovation of L'Oréal**.

Microeos develops new biological therapies based on phage and endolysin technology. **Microeos CEO Mark Offerhaus:** *"We expect this partnership to be ground-breaking. L'Oréal has been a leader in skincare for decades. Microeos is at the forefront of targeted bacterial biotechnology. We pair our strengths and millions stand to benefit"*. Microeos' pharma development program includes endolysins that all target Staphylococcus bacteria, which cause or aggravate a broad range of health issues, including skin conditions.

About Microeos

Microeos develops new biological therapies based on phage & endolysin technology. The company is considered the leader in this field. It developed the world's first endolysin-based products for human health, marketed under the Gladskin brand, and its technology was chosen as Europe's most impactful innovation in 2018. Headquartered in The Netherlands, with a central staff in The Hague, Microeos has a technology centre in Zurich, Switzerland and three separate business units: Pharma, OTC and Food Safety, with operations in the Netherlands and the USA. Microeos' pharma program includes compounds against *S. aureus* for atopic dermatitis, diabetic wound infections and sepsis. The company works closely together with ETH Zurich and many medical and technology centers, including Erasmus Medical Centre Rotterdam, the Public Health Lab Kennemerland, the Academic Centre for Dentistry Amsterdam and Copenhagen University.

About L'Oréal

L'Oréal has devoted itself to beauty for over 100 years. With its unique international portfolio of 36 diverse and complementary brands, the Group generated sales amounting to 29.87 billion euros in 2019 and employs 88,000 people worldwide. As the world's leading beauty company, L'Oréal is present across all distribution networks: mass market, department stores, pharmacies and drugstores, hair salons, travel retail, branded retail and e-commerce.

Research and innovation, and a dedicated research team of 4,100 people, are at the core of L'Oréal's strategy, working to meet beauty aspirations all over the world. L'Oréal sets out ambitious sustainable development goals across the Group for 2030 and aims to empower its ecosystem for a more inclusive and sustainable society.

More information: <https://mediaroom.loreal.com/>

"This press release does not constitute an offer of sale or solicitation of an offer to purchase L'Oréal shares. If you wish to obtain more comprehensive information about L'Oréal, please refer to the public documents registered in France with the Autorité des Marchés Financiers, also available in English on our website www.loreal-finance.com.

This press release may contain forecast information. While the Company believes that these statements are based on reasonable assumptions as of the date of publication of this press release, they are by nature subject to risks and uncertainties which may lead to a discrepancy between the actual figures and those indicated or suggested in these statements."

CONTACTS L'ORÉAL

Switchboard
+33 (0)1 47 56 70 00

Individual shareholders and market regulators

Christian MUNICH
+33 (0)1 47 56 72 06
Christian.munich2@loreal.com

Financial analysts and institutional investors

Françoise LAUVIN
+33 (0)147 56 86 82
Francoise.lauvin@loreal.com

Media

Polina HUARD
+33 (0)1 47 56 87 88
Polina.huard@loreal.com

For further information, please contact your bank, stockbroker or financial institution (I.S.J.N. code: FR000012031) and consult your usual newspapers or magazines or the Internet site for shareholders and investors, www.loreal-finance.com, the L'Oréal Finance app or call the toll-free number from France: 0 800 66 66 66.